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Aim: Although sorafenib is a standard drug for advanced hepatocellular carcinoma (HCC), little 
is known about a patient’s clinical course after treatment. We investigated the effect of 
post-progression survival (PPS) and progression-free survival (PFS) on overall survival (OS) in 
patients whose advanced HCC was treated by sorafenib. 
Methods: We searched in the PubMed database for reports with survival data of patients with 
HCC treated with sorafenib monotherapy, and selected reports with ≥ 20 patients each that 
provided data for both OS and PFS or time to progression (TTP). Median PPS (mPPS) was 
defined as the period obtained by subtracting median PFS or TTP (mPFS/TTP) from median OS 
(mOS). We identified 56 reports with 5803 patients. We investigated the correlation of mOS and 
either mPPS or mPFS/TTP using weighted linear regression. 
Results: Median PPS correlated with mOS (r=0.834) very strongly, whereas mPFS/TTP did not 
correlate with mOS as highly as PPS did (r=0.546). When we stratified survival data by 
Child-Pugh classification, a significantly greater average percentage of mPPS to mOS was seen 
in Child-Pugh class A (54.4±17.6 %) than in Child-Pugh class B (32.0±11.6 %) (P=0.015). 
Conclusions: PPS highly correlated with OS, and its importance should be more emphasized 
for advanced HCC patients treated after sorafenib therapy, whereas we need to take more care in 
interpreting the results of PFS to evaluate treatment efficacy in clinical trial of advanced HCC. 
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Some anti-cancer therapies are effective even for disease that is refractory to first-line 
chemotherapy agents. The duration of disease progression from first-line treatment to death is 
defined as post-progression survival (PPS), and can be prolonged as active agents become 
available at subsequent treatment 1-4. Consequently overall survival (OS), which is considered to 
be the optimal endpoint for cancer patients who could not receive curative therapy, has been 
strongly correlated with PPS in non-small-cell lung cancer, gastric cancer, colorectal cancer, and 
breast cancer 1-4, and this tendency has been stronger in recent trials than that in older trials 1-3. 
The association between progression-free survival (PFS) and OS is moderate at best in these 
malignancies because it becomes weaker as the proportion of PPS to OS increases 5. Conversely, 
PFS supposedly correlates well with OS in some malignancies, such as pancreatic cancer, 
melanoma and older trials of colorectal cancer 6, 7, in which PPS remains short because the 
advantage of second-line chemotherapy is limited 8 and the biological malignancy is very 
potent. 
 Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause 
of cancer-related mortality worldwide 9. A variety of new imaging techniques have enabled 
early-stage detection of HCC 10, and advances in various therapeutic procedures such as liver 
transplantation and radiofrequency ablation have improved its curability 11. However, patients 
with HCC who can be treated curatively have unsatisfactory prognosis because of frequent 
recurrence even after curative therapy. The prognosis of patients whose advanced HCC has 
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spread over the liver or invaded major vessels remains very poor 12. 
 Sorafenib, an oral multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, 
is the only systemic therapy that has significantly improved OS compared with placebo for 
patients with advanced HCC 13, 14. It is recognized as standard first-line chemotherapy for 
advanced HCC 15, 16. Alternative systemic chemotherapies using cytotoxic agents or novel 
targeted drugs have been attempted in patients with advanced HCC. Some of agents 
significantly prolonged PFS compared to that of control group; however, they did not improve 
OS in phase III trials 17. 
 Under such circumstances, better understanding of PPS and PFS will clarify any problems of 
those failed trials and lead new agents to successful development. The present study reviewed 
clinical literature to investigate the effect of PPS and PFS on OS for patients with advanced 
HCC treated by sorafenib. 
 
Materials and Methods 
Search and selection of literatures 
 We searched medline database through PubMed citations up to 20 December, 2013. Key words 
included in the search were “hepatocellular carcinoma” and “sorafenib.” The search was limited 
to reports describing clinical data of patients with HCC treated by a single-medication sorafenib 
and published in English. We selected all reports that provided analyzed intent-to-treat data for 
OS and either PFS or time-to-progression (TTP), whether or not these parameters were 
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explicitly defined. We included reports in which primary endpoints were not OS or PFS and 
reports of prospective clinical trials or retrospective clinical practice, and single arms of 
multi-arm studies if each arm dealt with at least 20 patients. We excluded review articles, case 
reports, letters or commentaries, interim analysis, subgroup analyses of previously reported 
trials, or duplicates. Reports in which all or some patients were treated as adjuvant setting or 
neoadjuvant setting, or with concomitant treatment, including resection, transplantation, 
transarterial chemoembolization, or radiation therapy in addition to sorafenib were also 
excluded. To avoid bias, two specialists in HCC (T.T. and N.T.) independently reviewed and 
selected the articles and extracted the data from the reports. 
 
Data collection 
 For the sake of simplicity, TTP data were also collectively referred to as that of PFS in the 
present analysis if PFS was not addressed; similar to an approach adopted in a recent reposts 1-4. 
Median OS (mOS) and median PFS or median TTP (mPFS/TTP) were extracted from all reports 
that provided data. Median PPS (mPPS) was defined as the period obtained by subtracting 
mPFS/TTP from mOS for each report 1-4. Survival data were converted to months; 30.45 days 
were converted to 1 month in reports that described survival data in days or weeks. We also 
obtained the following information from each report: number of arms in each report, 
characteristics of the reports, number of patients in each arm, criteria of radiological responses, 





 We summarized the survival data (mOS, mPFS/TTP, and proportion of mPPS/mOS) as the 
average for all treatment arms. The relationship between mOS and either mPFS/TTP or mPPS 
was estimated using weighted linear regression, with weights equal to the sample size of the 
arms from which the data were derived 18. If the reports described the survival data stratified by 
Child-Pugh classification, we obtained the respective data. Student’s t-test was used to assess 
differences in proportions of mPPS to mOS stratified by Child-Pugh classification. All reported 
P-values correspond to two-sided tests, with P <0.05 considered to be statistically significant. 
Data analyses used Stata 12.1 (College Station, TX, USA). 
 
Results 
Characteristics of the trials 
 We found a total of 1171 publications from the search for medline database through PubMed, 
but excluded 780 reports for at least one of the following reasons: not in English (n=104), case 
report (n=127), preclinical assessment (n=261), study of other treatment modalities, neoadjuvant 
setting, adjuvant setting, with concomitant treatment (n=200), review articles, letters, 
commentaries, conference records, and other assessment of sorafenib (n=338), interim analysis, 
subgroup analyses of previously reported trial duplicates (n=12), consisted of 19 or less patients 
(n=30), without information about mOS and/or mPFS/TTP (n=38), and/or not intention-to-treat 
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analyses (n=5). The remaining 56 reports met the inclusion criteria of the present study (Figure 
1). Characteristics of the 56 reports in our study, with 61 arms and 5803 patients with advanced 
HCC, are shown in Table 1 and Supplementary Table 1. 
 
Survival data and relations between OS and either PFS/TTP or PPS 
 The mPPS of all trials had a range of 0.4–18.1 months; mPPS was 4.8±3.2 months (mean ± 
standard deviation; SD). The mOS and the mPFS/TTP had a range of 2.7–26.1 months and 
1.9–12.0 months, respectively, and 8.9±3.8 months and 4.0±1.9 months (mean ±SD), 
respectively. The average proportion (±SD) of mPPS to OS for all patients was 51.8±17.4%. 
 The mOS among the 61 arms were plotted against mPPS (Figure 2), and mPFS/TTP (Figure 3). 
We found mPPS was strongly correlated with mOS (r=0.834, P<0.001) based on weighted 
linear regression (Figure 2). However, mPFS/TTP did not correlate with mOS as highly as PPS 
did (r=0.546, P<0.001; Figure 3). 
 Similar tendencies were observed among the reports in which tumor progression was assessed 
by PFS (Supplementary Figure 1) and TTP (Supplementary Figure 2), and in which radiological 
responses were assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 
(Supplementary Figure 3) and modified RECIST (Supplementary Figure 4). 
 
Survival data according to Child-Pugh classification 
 Survival data stratified by Child-Pugh classification were obtained from only 10 arms in 
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Child-Pugh class A and 6 arms in Child-Pugh class B. Average PPS and OS (±SD) were 
significantly longer in Child-Pugh class A (4.8±1.6 months and 9.3±2.4 months) than in 
Child-Pugh class B (1.6±1.0 months; P=0.0011 and 4.5±1.9 months; P=0.0005, respectively). 
Average PFS tended to be longer, but not significantly so, in Child-Pugh class A (4.5±3.1 
months) than in Child-Pugh class B (3.0±1.0 months) (P=0.28). The average proportion of 
mPPS against mOS was significantly higher in Child-Pugh class A than in Child-Pugh class B 





 Our analysis demonstrated that PPS is highly correlated with OS, whereas PFS is less 
correlated with OS in this patient population. This result was unexpected and interesting 
because PFS rather than PPS has been considered to correlate strongly with OS in advanced 
HCC patients from the perspective of the fact that no treatment has shown to be effective after 
sorafenib in prospective study 17. While in patients with other cancers such as breast cancer, 
colorectal cancer, or non-small-cell lung cancer for which several effective agents are available 
after first-line chemotherapy, PPS strongly correlated with OS 1-4. 
 Although the precise reason for this strong correlation between PPS and OS was unclear, a 
possible reason was the role of multidisciplinary therapy in HCC. Such alternative therapies as 
hepatic arterial infusion chemotherapy 19 and radiation 20 as well as continuous administration of 
sorafenib beyond progression 21 have been conventionally conducted as subsequent therapy 
because they have been thought to be efficacious even after sorafenib therapy 22, 23 although 
such opinions had not been established in proper prospective trials. Although this study could 
not analyze the effect of subsequent therapies on PPS and OS because of the absence of 
individual information about subsequent therapies, multidisciplinary approaches may have the 
impact of PPS on HCC, as seen in other cancers for which many effective agents have been 
successfully developed. 
 Another consideration was most subjects in this study had good hepatic reserve, as the 
feasibility and efficacy of sorafenib for patients with Child-Pugh class B/C is unclear 24, and 
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sorafenib is usually administrated in patients with Child-Pugh class A cirrhosis or without liver 
cirrhosis. Our results, the proportion of mPPS against mOS was higher in Child-Pugh class A 
than in Child-Pugh class B, also suggested good hepatic reserve may enable patients to benefit 
more from subsequent therapy after sorafenib and to have longer PPS than our assumption 25. In 
addition to contribution to PPS prolongation of subsequent therapy after sorafenib itself, better 
natural prognosis which may affect the strong correlation between PPS and OS in this study. 
 Our result, which clarified the strong correlation between PPS and OS in advanced HCC 
treated with sorafenib, showed the necessity of considering PPS. For example, survival time of 
the patients in control group was actually longer than that of hypothesis in recent randomized 
control trials which was conducted as second-line setting after sorafenib therapy 26, which may 
lead these trials to insufficient difference in OS because it was reported that long PPS 
diminishes the effect of agents on OS in clinical trials 5. Some reports showed that PPS 
depended on patterns of tumor progression, clinical stage, reasons of discontinuation of 
sorafenib 27, 28. Successful development of novel therapies needs better understanding of such 
factors as different hazard ration of PPS according to tumor progression patterns, clinical stage, 
or hepatic reserve in trial design, and additional information including subsequent therapy or 
progression pattern should be checked in trial analysis. 
 Conversely, the following reasons were speculated to explain the weak correlation between 
PFS and OS in these patients. First, HCC progression is assessed heterogeneously; although 
radiology and other imaging is used to judge response to anti-cancer drugs in solid tumors, 
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clinical criteria or follow-up intervals were not standardized in this study 29. Determining tumor 
progressions unlike tumor responses were reported to be corresponding in conventional 
RECIST and modified RECIST 30, 31, and similar results were observed in this study in subgroup 
analysis among the reports in which conventional RECIST and modified RECIST were used as 
tool of radiological assessments (Supplementary Figure 3 and 4), which suggested that the 
variation of assessment tool had minimal effects. Second, hepatic reserve affects survival in 
HCC 25, 32. Hepatic reserve often restricts OS independently of PFS which is purely restricted by 
antitumor effect. To minimalize the effect of the death without tumor progression for 
understanding these results, we conducted subgroup analyses separately among the reports dealt 
with PFS and TTP, and confirmed that similar results were observed (Supplementary Figure 1 
and 2). Third, the present study showed that, among patients with Child-Pugh class A, PPS was 
more than half of OS, which accords with recent findings for breast cancer and colon cancer, 
although the average PPS of 4.8 months was not long compared with those cancers. Weaker 
correlation between PFS and OS may thus be induced from the greater proportion of PPS to OS 
in patients with better hepatic reserve 5. 
 OS is usually set as the primary endpoint for the pivotal study in advanced HCC area because 
it is considered that the primary endpoint should be the endpoint which can directly evaluate 
purpose of the treatment for study patients, and true purpose for the patients with advanced 
HCC was longer survival. This attitude in advanced HCC area is corresponded to that of 
regulating authority which was assigned to evaluation of the efficacy of novel agents. On the 
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other hand, PFS is commonly recognized as an alternative endpoint especially for early-phase 
studies to evaluate the efficacy of novel agents for advanced HCC over a short time 27, 33. In this 
study, however, the correlation between OS and PFS seemed to be too weak to establish PFS as 
surrogate endpoint of OS. This is consistent with a perspective that PFS had favorable tendency 
whereas prolongation of OS weren’t observed in recent clinical trials 34, therefore we need to 
take more care in interpreting the results of PFS to evaluate the efficacy of new agents or 
treatments and judging whether it has efficacy to proceed to phase III trial based not only 
PFS/TTP but also that of OS especially in early-phase studies of advanced HCC. Of course, 
sorafenib prolonged TTP as well as OS compared with placebo in large phase III trials 13, 14, and 
we did not deny the significance of PFS prolongation obtained by sorafenib therapy in advanced 
HCC patients from our findings that median PFS was also correlated with median OS 
statistically. The prolongation of PFS obtained by sorafenib therapy probably contributes that of 
OS, and the prolongation of PPS may also contribute that of OS based on our results. 
 There had been few reports of randomized control trial in advanced HCC, therefore we 
collected all reports which met our inclusion criteria; however, we could not fully ensure the 
quality of these reports. Then some phase III trials have been reported after the time of our 
analysis, and we additionally investigated the correlation of OS and PPS or TTP using 
information of these trials describing about survival data of sorafenib monotherapy because they 
were similar design (Supplementary Table 2). In consequence, median PPS correlated with mOS 
strongly (r=0.804), whereas mTTP did not correlate with mOS as highly as PPS did (r=0.396) 
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as shown in Figure 5, which supported our results of all reports although still limited number of 
trials did not allow reaching any definite conclusion. Other limitations included lack of detail of 
individual patient data, potential confounders because of the inclusion of many heterogeneous 
trials, and selection and publication bias. Further investigation with information of individual 
patients including subsequent therapy and progression pattern is needed to confirm our findings. 
 
Conclusion 
 In conclusion, among patients with advanced HCC patients treated with sorafenib, PPS highly 
correlates with OS, which should be noticeable for these patients in the design and analysis of 
clinical trials and in daily practice. However, PFS appears not to be a suitable surrogate 
endpoint for OS for advanced HCC. 
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Figure 1: Study flow diagram 
 
Figure 2: Relationship between median overall survival and median post-progression survival 
among all reports. Each arm is represented by a circle, with a size proportional to the number of 
patients. Median post-progression survival was strongly correlated with median overall survival 
(r=0.834, P<0.001) on the basis of weighted linear regression. 
 
Figure 3: Relationship between median OS and median progression-free survival among all 
reports. Each arm is represented by a circle, with a size proportional to the number of patients. 
Median PFS/TTP was moderately correlated with median OS (r=0.546, P<0.001) on the basis of 
weighted linear regression. 
 
Figure 4: Average proportion of median PPS to median OS according to Child-Pugh class. The 
average of median PPS/median OS in Child-Pugh class A (54.4±17.6 %) was significantly 
higher than in Child-Pugh class B (32.0±11.6 %) (P=0.015). 
 
Figure 5: Relationship between median overall survival median post-progression survival or 
progression-free survival among phase III trials. (A) Relationship between median overall 
survival (OS) and median post-progression survival (PPS), and (B) relationship between median 
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OS and median progression-free survival (PFS) or median time to progression (TTP) among 
reports of phase III trials. Each arm is represented by a circle, with a size proportional to the 
number of patients. Median PPS was strongly correlated with median OS (r=0.804), and median 
PFS/TTP was moderately correlated with median OS (r=0.396) on the basis of weighted linear 
regression. 
 
Supplementary Figure 1: (A) Relationship between median overall survival (OS) and median 
post-progression survival (PPS) and (B) relationship between median OS and median 
progression-free survival (PFS) among the reports in which tumor progression was assessed by 
PFS. Each arm is represented by a circle, with a size proportional to the number of patients. 
Median PPS was strongly correlated with median OS (r=0.952, P<0.001) on the basis of 
weighted linear regression. On the other hand, median PFS had no correlation with median OS 
(r=0.064, P=0.773). 
 
Supplementary Figure 2: (A) Relationship between median overall survival (OS) and median 
time to progression (TTP) and (B) relationship between median OS and median 
progression-free survival (PFS) among the reports in which tumor progression was assessed by 
TTP. Each arm is represented by a circle, with a size proportional to the number of patients. 
Median PPS was strongly correlated with median OS (r=0.795, P<0.001) on the basis of 
weighted linear regression. On the other hand, median TTP was moderately correlated with 
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median OS (r=0.575, P<0.001). 
 
Supplementary Figure 3: (A) Relationship between median overall survival (OS) and median 
post-progression survival (PPS) and (B) relationship between median OS and median 
progression-free survival (PFS) or median time to progression (TTP) among the reports in 
which radiological responses were assessed by Response Evaluation Criteria In Solid Tumors 
(RECIST). Each arm is represented by a circle, with a size proportional to the number of 
patients. Median PPS was strongly correlated with median OS (r=0.870, P<0.001) on the basis 
of weighted linear regression. On the other hand, median PFS/TTP was weekly correlated with 
median OS (r=0.385, P=0.006). 
 
Supplementary Figure 4: (A) Relationship between median overall survival (OS) and median 
post-progression survival (PPS) and (B) relationship between median OS and median 
progression-free survival (PFS) or median time to progression (TTP) among the reports in 
which radiological responses were assessed by modified Response Evaluation Criteria In Solid 
Tumors. Each arm is represented by a circle, with a size proportional to the number of patients. 
Median PPS was strongly correlated with median OS (r=0.802, P<0.001) on the basis of 
weighted linear regression. On the other hand, median PFS/TTP was moderately correlated with 













Table Characteristics of the reports used in this study 
Number of reports 56 
 Number of arms in each report 
 
  1 52 
  2 3 
  3 1 
 Characteristics of the reports 
 
  Clinical trials 10 
  Clinical practice 46 
 
 
Number of arms 61 
 Number of patients in each arm  
  Median (Range) 57 (20-578) 
 Assessment of tumor progression  
  PFS 21 
  TTP 38 
  Both PFS and TTP 2 
 Criteria of radiological responses  
  RECIST 46 
  Modified RECIST 9 
  Both of RECIST and Modified RECIST 3 




Supplementary Table 1 List of reports and patients characteristics used in this study 





Child-Pugh class (n) 













A B C NDa 
Jeong SW Gut Liver. 2013;7:696-703. 30 57.6 21 17 13 0 0 30 19 RECIST 2.1 ND a 3.1 
Zheng YB Asian Pac J Cancer Prev. 2013;14:5527-31. 65 55 51 35 16 0 0 ND a 34 RECIST ND a 4.5 10 
Lee S PLoS One. 2013;8:e77240. 226 57 188 161 65 0 0 ND a 147 mRECIST 3 ND a 5.5 
Shin SY Int J Clin Pharmacol Ther. 2013;51:837-46. 99 55.57 87 83 16 0 0 ND a ND a RECIST ND a 2.57 6.3 
Johnson PJ J Clin Oncol. 2013;31:3517-24. 578 60 484 531 47 0 0 158 ND a mRECIST ND a 4.1 9.9 
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Supplementary Table 2 List of phase III trials and those patients characteristics used in additional analysis 
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A B C NDa 
Llovet JM N Engl J Med. 2008; 359: 278-90. 299 64.9 260 284 14 0 1 209 108 RECIST ND a 5.5 10.7 
Cheng AL Lancet Oncol 2009; 10: 25-34. 150 51 127 146 4 0 0 54 103 RECIST ND a 2.8 6.5 
Johnson PJ J Clin Oncol 2013; 31: 3517-24. 578 60 484 531 47 0 0 158 ND a mRECIST ND a 4.1 9.9 
Cheng AL J Clin Oncol 2013; 31: 4067-75. 544 59.0 459 541 1 0 2 415 ** RECIST 3.0 4.1 10.2 
Cainap C J Clin Oncol 2015; 33: 172-9. 521 60 436 493 26 0 2 211 296 RECIST ND a 4.0 9.8 
Zhu AX J Clin Oncol 2015; 33: 559-66. 358 60.0 286 345 0 0 13 153 219 RECIST ND a 4.0 8.5 
*. Median, **: Vascular invasion and/or extrahepatic spread 
a. ND: not described, b. MVI: Macroscopic vascular invasion, c. EHS: Extrahepatic spread 
 
 
 
